Eisai Co., Ltd. (TYO:4523)
5,137.00
+125.00 (2.49%)
Sep 5, 2025, 3:30 PM JST
Eisai Revenue
Eisai had revenue of 202.65B JPY in the quarter ending June 30, 2025, with 7.21% growth. This brings the company's revenue in the last twelve months to 803.02B, up 9.43% year-over-year. In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B with 6.42% growth.
Revenue (ttm)
803.02B
Revenue Growth
+9.43%
P/S Ratio
1.80
Revenue / Employee
73.56M
Employees
10,917
Market Cap
1,448.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.21B |
Takeda Pharmaceutical Company | 4,480.25B |
HOYA Corporation | 876.09B |
Daiichi Sankyo Company | 1,924.68B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |
Eisai News
- 3 days ago - Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 - PRNewsWire
- 4 days ago - Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose - Seeking Alpha
- 4 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. ... - GuruFocus
- 4 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Benzinga
- 4 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - PRNewsWire
- 8 days ago - US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug - Reuters
- 8 days ago - FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment - Investor's Business Daily
- 13 days ago - Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news - GuruFocus